138 related articles for article (PubMed ID: 38325713)
21. Evaluation of serum amino acid profiles' utility in non-small cell lung cancer detection in Polish population.
Klupczynska A; Dereziński P; Dyszkiewicz W; Pawlak K; Kasprzyk M; Kokot ZJ
Lung Cancer; 2016 Oct; 100():71-76. PubMed ID: 27597283
[TBL] [Abstract][Full Text] [Related]
22. Metabolic and lipidomic characterization of malignant pleural effusion in human lung cancer.
Yang Z; Song Z; Chen Z; Guo Z; Jin H; Ding C; Hong Y; Cai Z
J Pharm Biomed Anal; 2020 Feb; 180():113069. PubMed ID: 31884394
[TBL] [Abstract][Full Text] [Related]
23. Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study.
Maeda J; Higashiyama M; Imaizumi A; Nakayama T; Yamamoto H; Daimon T; Yamakado M; Imamura F; Kodama K
BMC Cancer; 2010 Dec; 10():690. PubMed ID: 21176209
[TBL] [Abstract][Full Text] [Related]
24. Serum Metabolomics Study of Nonsmoking Female Patients with Non-Small Cell Lung Cancer Using Gas Chromatography-Mass Spectrometry.
Mu Y; Zhou Y; Wang Y; Li W; Zhou L; Lu X; Gao P; Gao M; Zhao Y; Wang Q; Wang Y; Xu G
J Proteome Res; 2019 May; 18(5):2175-2184. PubMed ID: 30892048
[TBL] [Abstract][Full Text] [Related]
25. Integration of clinical phenoms and metabolomics facilitates precision medicine for lung cancer.
Yan F; Liu C; Song D; Zeng Y; Zhan Y; Zhuang X; Qiao T; Wu D; Cheng Y; Chen H
Cell Biol Toxicol; 2024 May; 40(1):25. PubMed ID: 38691184
[TBL] [Abstract][Full Text] [Related]
26. Combined analysis of gut microbiome and serum metabolomics reveals novel biomarkers in patients with early-stage non-small cell lung cancer.
Ni B; Kong X; Yan Y; Fu B; Zhou F; Xu S
Front Cell Infect Microbiol; 2023; 13():1091825. PubMed ID: 36743312
[TBL] [Abstract][Full Text] [Related]
27. Plasma metabolomics for the assessment of the progression of non-small cell lung cancer.
Zhang Y; Cheng Y; Qin L; Liu Y; Huang S; Dai L; Tao J; Pan J; Su C; Zhang Y
Int J Biol Markers; 2023 Mar; 38(1):37-45. PubMed ID: 36377344
[TBL] [Abstract][Full Text] [Related]
28. Serum lipidome screening in patients with stage I non-small cell lung cancer.
Klupczynska A; Plewa S; Kasprzyk M; Dyszkiewicz W; Kokot ZJ; Matysiak J
Clin Exp Med; 2019 Nov; 19(4):505-513. PubMed ID: 31264112
[TBL] [Abstract][Full Text] [Related]
29. Targeted metabolomic profiling as a tool for diagnostics of patients with non-small-cell lung cancer.
Shestakova KM; Moskaleva NE; Boldin AA; Rezvanov PM; Shestopalov AV; Rumyantsev SA; Zlatnik EY; Novikova IA; Sagakyants AB; Timofeeva SV; Simonov Y; Baskhanova SN; Tobolkina E; Rudaz S; Appolonova SA
Sci Rep; 2023 Jul; 13(1):11072. PubMed ID: 37422585
[TBL] [Abstract][Full Text] [Related]
30. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
31. Identifying potential biomarkers and therapeutic targets for dogs with sepsis using metabolomics and lipidomics analyses.
Montague B; Summers A; Bhawal R; Anderson ET; Kraus-Malett S; Zhang S; Goggs R
PLoS One; 2022; 17(7):e0271137. PubMed ID: 35802586
[TBL] [Abstract][Full Text] [Related]
32. Changes in serum amino acid levels in non-small cell lung cancer: a case-control study in Chinese population.
Liu K; Li J; Long T; Wang Y; Yin T; Long J; Shen Y; Cheng L
PeerJ; 2022; 10():e13272. PubMed ID: 35469201
[TBL] [Abstract][Full Text] [Related]
33. Discovery of potential therapeutic targets for non-small cell lung cancer using high-throughput metabolomics analysis based on liquid chromatography coupled with tandem mass spectrometry.
Xu HD; Luo W; Lin Y; Zhang J; Zhang L; Zhang W; Huang SM
RSC Adv; 2019 Apr; 9(19):10905-10913. PubMed ID: 35515291
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.
Yang ZY; Liu L; Mao C; Wu XY; Huang YF; Hu XF; Tang JL
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD009948. PubMed ID: 25400254
[TBL] [Abstract][Full Text] [Related]
35. Metabolic profiling of potential lung cancer biomarkers using bronchoalveolar lavage fluid and the integrated direct infusion/ gas chromatography mass spectrometry platform.
Callejón-Leblic B; García-Barrera T; Grávalos-Guzmán J; Pereira-Vega A; Gómez-Ariza JL
J Proteomics; 2016 Aug; 145():197-206. PubMed ID: 27255828
[TBL] [Abstract][Full Text] [Related]
36. Utilizing metabolomics to identify potential biomarkers and perturbed metabolic pathways in osteoarthritis: A systematic review.
Van Pevenage PM; Birchmier JT; June RK
Semin Arthritis Rheum; 2023 Apr; 59():152163. PubMed ID: 36736024
[TBL] [Abstract][Full Text] [Related]
37. Combined metabolomic and lipidomic analysis uncovers metabolic profile and biomarkers for papillary thyroid carcinoma.
Wang Z; Yang Y; Xing Y; Si D; Wang S; Lin J; Li C; Zhang J; Yin D
Sci Rep; 2023 Oct; 13(1):17666. PubMed ID: 37848492
[TBL] [Abstract][Full Text] [Related]
38. Subtyping non-small cell lung cancer by histology-guided spatial metabolomics.
Neumann JM; Freitag H; Hartmann JS; Niehaus K; Galanis M; Griesshammer M; Kellner U; Bednarz H
J Cancer Res Clin Oncol; 2022 Feb; 148(2):351-360. PubMed ID: 34839410
[TBL] [Abstract][Full Text] [Related]
39. Plasma Lipidomics Profiling to Identify the Biomarkers of Diagnosis and Radiotherapy Response for Advanced Non-Small-Cell Lung Cancer Patients.
Lv M; Shao S; Du Y; Zhuang X; Wang X; Qiao T
J Lipids; 2024; 2024():6730504. PubMed ID: 38312939
[TBL] [Abstract][Full Text] [Related]
40. Integrated metabolomics and lipidomics study of patients with atopic dermatitis in response to dupilumab.
Zhang L; Wen X; Hou Y; Yang Y; Song W; Zeng Y; Sun J
Front Immunol; 2022; 13():1002536. PubMed ID: 36341398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
